A recombinant enolase-montanide™ petgel a vaccine promotes a protective th1 immune response against a highly virulent sporothrix schenckii by toluene exposure

Página do item simplificado
dc.contributor.authorTéllez-Martínez, Damiana [UNESP]
dc.contributor.authorPortuondo, Deivys Leandro [UNESP]
dc.contributor.authorLoesch, Maria Luiza [UNESP]
dc.contributor.authorBatista-Duharte, Alexander [UNESP]
dc.contributor.authorCarlos, Iracilda Zeppone [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2019-10-06T16:27:21Z
dc.date.available2019-10-06T16:27:21Z
dc.date.issued2019-03-01
dc.description.abstractThe effect of vaccination in fungal strains that suffered changes in their virulence by exposure to environmental contaminants is largely known. Growing reports of resistance to antifungal drugs and the emergence of new highly virulent strains, possibly acquired in the environment, prompt the design of new vaccines able to prevent and combat emerging mycotic diseases. In this study, we evaluated the protective capacity of an enolase-based vaccine and Montanide PetGel A (PGA) as an adjuvant against S. schenckii with increased virulence by exposure to toluene. The adjuvanted vaccine induced a strong specific Th1 response and protective immunity against a challenge with either wildtype or toluene-adapted S. schenckii in Balb/c mice. This study highlights the role of the adjuvant PGA driving the quality of the anti-sporothrix immunity and the key component in the vaccine efficacy.en
dc.description.affiliationDepartment of Clinical Analysis School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Clinical Analysis School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: 2017/26774-3
dc.format.extent1-13
dc.identifierhttp://dx.doi.org/10.3390/pharmaceutics11030144
dc.identifier.citationPharmaceutics, v. 11, n. 3, p. 1-13, 2019.
dc.identifier.doi10.3390/pharmaceutics11030144
dc.identifier.issn1999-4923
dc.identifier.scopus2-s2.0-85064739891
dc.identifier.urihttp://hdl.handle.net/11449/189025
dc.language.isoeng
dc.relation.ispartofPharmaceutics
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectAdjuvants
dc.subjectEnolase
dc.subjectMontanide PetGel A
dc.subjectSporothrix schenckii
dc.subjectToluene
dc.subjectVaccine
dc.subjectVirulence
dc.titleA recombinant enolase-montanide™ petgel a vaccine promotes a protective th1 immune response against a highly virulent sporothrix schenckii by toluene exposureen
dc.typeArtigo

Arquivos

Coleções

Artigos - Análises Clínicas - FCFAR